Hexagon Nutrition Limited, a research-driven company in India's nutrition and wellness sector, has launched its Initial Public Offering (IPO). The offering provides a window for public investment into a company with an established presence in clinical nutrition and product formulation.
This article outlines the essential details of the Hexagon Nutrition IPO, covering its financial performance, business structure, and key timelines.
IPO Details & Timeline
The Hexagon Nutrition IPO is a mainboard, book-built offering. The key parameters for investors are detailed below:
| Bidding Period | June 5, 2026 – June 9, 2026 |
| Price Band | ₹42 – ₹45 per equity share |
| Base Lot Size | 333 Shares |
| Minimum Retail Application | 1 Lot (333 Shares) |
| Minimum Retail Investment | ₹14,985 (at the ₹45 upper price band) |
| Listing Platform | BSE & NSE (Mainboard) |
| Total Issue Size | ₹138.87 Cr (3,08,59,704 Equity Shares) |
| Issue Type | 100% Offer For Sale (OFS) |
| Tentative Listing Date | June 12, 2026 |
About the Company
Founded in 1993, Hexagon Nutrition Limited operates as a pure-play brand focused on human nutrition, preventive health supplements, and clinical dietary products. Hexagon Nutrition's distribution network is omnichannel, encompassing retail pharmacies, e-commerce platforms, and corporate hospitals, supported by over 358 distribution partners in India. The company has a global reach, with exports to more than 75 countries.
The company's business is structured across three core verticals:
- Branded Wellness & Clinical Nutrition (B2C): This division offers specialized consumer products for disease management, recovery, and general wellness. The portfolio includes brands such as Pentasure, Obesigo, Pediagold, and Nutrone.
- Premix Formulation Solutions (B2B2C): The company manufactures customized vitamin and mineral premixes that are supplied to major domestic and multinational FMCG companies for use in their end products.
- Ready-to-Use Foods (RUFs) & Micronutrient Powders (MNPs): This vertical focuses on therapeutic nutrition solutions for institutional procurement, including global aid programs and public health entities operating under ESG frameworks.
Financial Snapshot
The company's consolidated financial performance over recent fiscal periods is detailed below.
(All figures in ₹ Crores)
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Total Income | ₹331.29 | ₹304.62 | ₹278.50 |
| Profit After Tax (PAT) | ₹24.38 | ₹12.21 | ₹5.82 |
Financial Highlights:
- The company has shown significant growth in net profitability, with Profit After Tax (PAT) increasing from ₹5.82 Crores in FY23 to ₹24.38 Crores in FY25.
- EBITDA margins have improved, reaching 14.03% in the nine months ending December 31, 2025.
- The company maintains a relatively low debt-to-equity ratio of 0.18.
Objects of the Issue
- Promoter Stake Divestment: To allow the promoter and promoter group entities, to liquidate a portion of their equity holdings.
- Enhanced Brand Visibility: Listing on the BSE and NSE is expected to increase the company's brand stature and improve market transparency, which can be beneficial for its relationships with institutional buyers and multinational partners.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
.png)
.png)
